Tetherex Pharmaceuticals Stock

tetherex.comBioTechFounded: 2002Funding to Date: $70.84MM

Developer of drugs for the treatment of inflammatory and thrombotic diseases. The company's treatment program is built around an antibody called SelK2 directed against the cell adhesion molecule P-Selectin Glycoprotein Ligand-1 (PSGL-1).

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for Tetherex Pharmaceuticals, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Scott Rollins Ph.D
Chief Executive Officer, Co-Founder & Chairman
Russell Rother Ph.D
President, Board Member & Chief Operating Officer
Ziad Kawar Ph.D
Senior Scientist
Richard Cummings Ph.D
Co-Founder
Jonathan Stocker Ph.D
Senior Director, Clinical Development
Richard Alvarez
Vice President, Operations & Research
David Falconer
Vice President, Quality and Program Management

Board Members

David Keiser
Philip Jones MD
Rodger McEver MD
Scott Rollins Ph.D
Todd Foley
MPM Capital

Other companies like Tetherex Pharmaceuticals in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM